PHASE 1B STUDY OF PTC299 IN RELAPSED/REFRACTORY ACUTE LEUKEMIAS
Study of PTC299 in Relapsed/Refractory Acute Leukemias
Sponsor: PTC THERAPEUTICS, INC.
Enrolling: Male and Female Patients
IRB Number: AAAS1730
U.S. Govt. ID: NCT03761069
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to find if PTC299 is safe to treat people with relapsed/refractory acute myeloid leukemia (AML) as well to determine the dose of PTC299 that can be given without causing severe side effects. AML is a cancer of the blood and bone marrow (spongy tissue inside bones where blood cells are made). PTC299 is being developed to potentially treat leukemias. Approximately 18-36 adult subjects (at least 18 years of age) with relapsed/refractory AML will take part in this study, at 3-8 sites in the US.
This study is closed
Investigator
Joseph Jurcic, MD
Do You Qualify?
Are you 18 years of age? Yes No
Do you have diagnosis of relapsed/refractory AML? Yes No
Do you agree to not participate in another study while on treatment for this study? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162